Numerical Simulation Research of Natural Convection Heat Exchanger
In this paper, computer software is employed to simulate the temperature-field and flow-field of AP1000 PRHR HX, and investigate its heat-transferring and flow characteristic. Through comparative analysis of the distribution of temperature-field and flow-field in different locations at the same time, and the change of temperature-field and flow-field in the same location at different times, heat-transferring process and natural convection situation of PRHR HX are deeply understand. It contributes to analyze the natural circulation capacity of PRHR HX, and provides some references for the effective operation of passive residual heat removal system.
Testing of Passive Safety System Performance for Higher Power Advanced Reactors
This report describes the results of NERI research on the testing of advanced passive safety performance for the Westinghouse AP1000 design. The objectives of this research were: (a) to assess the AP1000 passive safety system core cooling performance under high decay power conditions for a spectrum of breaks located at a variety of locations, (b) to compare advanced thermal hydraulic computer code predictions to the APEX high decay power test data and (c) to develop new passive safety system concepts that could be used for Generation IV higher power reactors.
Design and synthesis of water-soluble prodrugs of rifabutin for intraveneous administration.
Acinetobacter baumannii is a gram-negative bacterium causing severe hospital-acquired infections such as bloodstream infections or pneumonia. Moreover, multidrug resistant A. baumannii becomes prevalent in many hospitals. Consequently, the World Health Organization made this bacterium a critical priority for the research and development of new antibiotics. Rifabutin, a semisynthetic product from the rifamycin class, was recently found to be very active in nutrient-limited eukaryotic cell culture medium against various A. baumannii strains, including extremely drug-resistant strains, with minimal inhibitory concentrations as low as 0.008 μg/mL. Moreover, this in vitro potency translates into in vivo efficacy. Thus, rifabutin appears to be an attractive novel antibiotic against A. baumannii. In this work, our objective was to design and synthetize rifabutin prodrugs with increased aqueous solubility to allow intraveneous use. Synthetic methodologies were developed to selectively functionalize the hydroxyl group in position 21 and to afford 17 prodrugs. We measured the water solubility of the prodrugs, the stability in human and mouse plasma and their antimicrobial activity against A. baumannii after incubation in human serum. Finally, a pharmacokinetic release study of rifabutin was performed in CD1 mice with three selected prodrugs as a proof of concept.